JPH10512453A - ヒト インターロイキン−１ レセプター アクセサリータンパク質 - Google Patents

ヒト インターロイキン−１ レセプター アクセサリータンパク質

Info

Publication number
JPH10512453A
JPH10512453A JP8522598A JP52259896A JPH10512453A JP H10512453 A JPH10512453 A JP H10512453A JP 8522598 A JP8522598 A JP 8522598A JP 52259896 A JP52259896 A JP 52259896A JP H10512453 A JPH10512453 A JP H10512453A
Authority
JP
Japan
Prior art keywords
acp
cells
protein
human
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8522598A
Other languages
English (en)
Japanese (ja)
Inventor
アンソニー チゾニテ，リチャード
ウォン ユー，グレイス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JPH10512453A publication Critical patent/JPH10512453A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP8522598A 1995-01-23 1996-01-17 ヒト インターロイキン−１ レセプター アクセサリータンパク質 Pending JPH10512453A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37626895A 1995-01-23 1995-01-23
US08/376,268 1995-01-23
PCT/EP1996/000181 WO1996023067A1 (fr) 1995-01-23 1996-01-17 Proteine accessoire humaine du recepteur de l'interleukine-1

Publications (1)

Publication Number Publication Date
JPH10512453A true JPH10512453A (ja) 1998-12-02

Family

ID=23484321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8522598A Pending JPH10512453A (ja) 1995-01-23 1996-01-17 ヒト インターロイキン−１ レセプター アクセサリータンパク質

Country Status (19)

Country Link
EP (1) EP0808365A1 (fr)
JP (1) JPH10512453A (fr)
AR (1) AR003919A1 (fr)
AU (1) AU4537096A (fr)
BR (1) BR9606837A (fr)
CA (1) CA2210724A1 (fr)
CO (1) CO4480033A1 (fr)
CZ (1) CZ208197A3 (fr)
EA (1) EA199700265A1 (fr)
FI (1) FI973089A0 (fr)
HU (1) HUP9702458A2 (fr)
IL (1) IL116796A0 (fr)
MX (1) MX9705501A (fr)
NO (1) NO973404L (fr)
PE (1) PE64396A1 (fr)
PL (1) PL321538A1 (fr)
TR (1) TR199700652T1 (fr)
WO (1) WO1996023067A1 (fr)
ZA (1) ZA96333B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502403A (ja) * 2009-08-21 2013-01-24 カンタージア アクチエボラーグ 新規な薬剤及びその使用
JP2014511348A (ja) * 2011-01-19 2014-05-15 カンタージア アクチエボラーグ 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP0979282A1 (fr) 1997-04-30 2000-02-16 F. Hoffmann-La Roche Ag Chemokine st38.2 du rat
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
EP1042477A1 (fr) 1997-12-23 2000-10-11 Immunex Corporation Adn et polypeptides sigirr
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU2002253842A1 (en) 2000-10-31 2002-08-28 Immunex Corporation Il-1 receptor accessory protein
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク． Ｏｐｇｌへの抗体
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
WO2003014309A2 (fr) * 2001-08-07 2003-02-20 Immunex Corporation Recepteurs de l'interleukine-1 dans le traitement de maladies
ATE549033T1 (de) 2002-09-06 2012-03-15 Amgen Inc Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
TR201816556T4 (tr) 2004-04-02 2018-11-21 Swedish Orphan Biovitrum Ab Publ Il-1ra agregasyonunun azaltilmasina yöneli̇k yöntemler
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
CA2607113C (fr) * 2004-05-05 2013-11-12 Valorisation-Recherche, Societe En Commandite Antagonistes du recepteur de l'interleukine-1, compositions, et methodes de traitement
EP2366786A3 (fr) * 2005-05-05 2012-08-29 VALORISATION HSJ, Société en Commandite Modulateurs de récepteur de cytokine et utilisations associées
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
EP2271673B1 (fr) 2008-03-26 2016-02-24 Cellerant Therapeutics, Inc. Récepteurs de cytokine associés aux troubles prolifératifs hématologiques myélogènes et utilisations correspondantes
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
MX2013013627A (es) * 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
WO2013006490A2 (fr) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Anticorps se liant spécifiquement à tim3
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
EP3294906A1 (fr) 2015-05-11 2018-03-21 Natera, Inc. Procédés et compositions pour la détermination de la ploïdie
EP3313887A2 (fr) 2015-06-26 2018-05-02 MAB Discovery GmbH Anticorps monoclonaux anti-il-1racp
EP3241845A1 (fr) 2016-05-06 2017-11-08 MAB Discovery GmbH Anticorps anti-il-1r3 humanisés
WO2018022982A1 (fr) 2016-07-29 2018-02-01 Trustees Of Boston University L'hématopoïèse clonale associée à l'âge accélère le développement d'une maladie cardio-métabolique
EP3401332A1 (fr) 2017-05-08 2018-11-14 MAB Discovery GmbH Anticorps anti-il-1r3 destinés à être utilisés dans des conditions inflammatoires
JP2020524519A (ja) 2017-06-20 2020-08-20 ザ メディカル カレッジ オブ ウィスコンシン，インコーポレイテッドＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． 全セルフリーｄｎａによる移植合併症リスクの評価
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021236962A1 (fr) 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions et méthodes d'inhibition du syndrôme de libération des cytokines
WO2022247937A1 (fr) * 2021-05-28 2022-12-01 Biocytogen Jiangsu Co., Ltd. Animal non humain génétiquement modifié exprimant l'il1rap humaine ou chimérique

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502403A (ja) * 2009-08-21 2013-01-24 カンタージア アクチエボラーグ 新規な薬剤及びその使用
JP2014511348A (ja) * 2011-01-19 2014-05-15 カンタージア アクチエボラーグ 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用

Also Published As

Publication number Publication date
NO973404D0 (no) 1997-07-23
AR003919A1 (es) 1998-09-30
CO4480033A1 (es) 1997-07-09
WO1996023067A1 (fr) 1996-08-01
ZA96333B (en) 1996-07-23
FI973089A (fi) 1997-07-22
EA199700265A1 (ru) 1998-04-30
MX9705501A (es) 1997-10-31
HUP9702458A2 (hu) 1998-04-28
PL321538A1 (en) 1997-12-08
IL116796A0 (en) 1996-05-14
CA2210724A1 (fr) 1996-08-01
AU4537096A (en) 1996-08-14
BR9606837A (pt) 1998-05-26
EP0808365A1 (fr) 1997-11-26
PE64396A1 (es) 1997-01-28
FI973089A0 (fi) 1997-07-22
NO973404L (no) 1997-07-23
TR199700652T1 (xx) 1998-02-21
CZ208197A3 (en) 1997-11-12

Similar Documents

Publication Publication Date Title
JPH10512453A (ja) ヒト インターロイキン−１ レセプター アクセサリータンパク質
US6372899B1 (en) Purified genes encoding mammalian cell surface antigens; proteins and antibodies
JP3520272B2 (ja) リンパ球機能関連抗原３のｃｄ２結合ドメイン
EP0991759A1 (fr) Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)
WO1998055620A1 (fr) Element ntn-2 de la famille des ligands du tnf
JP2001157593A (ja) 哺乳動物ケモカインｃｃｆ１８およびレセプターｃｃｋｒ３
WO1994017184A1 (fr) Modulation de la reponse physiologique de lymphocytes par les molecules cd38 ou leurs anti-corps
WO1996029348A1 (fr) Anticorps monoclonal dirige contre la proteine receptrice 4-1bb d'origine humaine et procedes d'utilisation de cet anticorps pour le traitement des maladies
CA2299619A1 (fr) Nouveau recepteur orphelin
JP2001512017A (ja) 哺乳動物細胞膜タンパク質；関連試薬
JP2001507219A (ja) 単離された哺乳動物単球細胞遺伝子；関連する試薬
JP2001501813A (ja) 分泌蛋白およびそれらをコードするポリヌクレオチド
JPH08510907A (ja) リンパ球化学誘引因子およびその用途
JP2003523735A (ja) ヒトナチュラルキラー細胞によって媒介される天然細胞毒性に関連した新規トリガリングレセプターおよび同一の性質を有する抗体
JPH11507513A (ja) Ｃ５ａ様７膜貫通受容体
KR100676229B1 (ko) 신경영양성 인자 수용체
US5728548A (en) Retinoid receptor-1 (RR1) and DNA encoding RR1
WO1998009638A1 (fr) INHIBITION DE L'ACTIVATION DES MASTOCYTES PAR DES MECANISMES ET DES REACTIFS A BASE DE gp49
JP2000515726A (ja) 分泌蛋白をコードする成人ｐｂｍｃ由来のポリヌクレオチド
EP0795014B1 (fr) SLAM, antigène costimulant de surface de cellules T
EP1027436A1 (fr) Adn et polypeptides recepteurs des proteines de semaphorine a codage viral
KR20010043088A (ko) 신규인 폴리펩티드, 그 폴리펩티드를 코드화하는 ｃＤＮＡ및 그 용도
WO2000032633A1 (fr) Nouvelle molecule d'adhesion et procedes d'utilisation
WO1995002611A1 (fr) Proteine de surface cellulaire presente sur les cellules tueuses naturelles appelee dx1
JP2000508908A (ja) 分泌蛋白およびそれらをコードしているポリヌクレオチド